Oncology - for many, this word sounds like a death sentence. It is noteworthy that every year, judging by the statistics, the number of people diagnosed with malignant tumors is growing. Moreover, breast cancer with metastases is the most common pathology that occurs in women of childbearing age. It is in this regard that a drug was developed called Kadcyla (Trastuzumab) - Kadcyla (Trastuzumab) . Consider the necessary information about it, what effect can be achieved using the drug, and what side effects it can cause.
The agent is a monoclonal antibody for the treatment of patients who have been diagnosed with breast cancer with metastases. The mechanism of action is that the main active substance acts on malignant cells, stopping their growth by telling the immune system that malignant cells must be eradicated. For Kadcyla (Trastuzumab) - Kadcyla (Trastuzumab) pricehigh, however, the drug is very popular. This is due to the fact that the drug does an excellent job with its task, with a minimum of side effects. Manufacturing company - Roche. Even in patients for whom doctors do not guarantee recovery, the drug has shown excellent results. Thanks to therapy, you can improve the quality of life, as well as extend it more than three times (results of clinical trials). Side effects are present, but they are much less, they are much easier to endure - it is all of the above factors that give an answer to the question of why most patients tend to buy Kadcyla (Trastuzumab) - Kadcyla (Trastuzumab) .
©2020 CopyRight Onco24.com. All rights reserved.